Table 5.

Cox's proportional hazard model in EGFR-negative patients (erlotinib, n = 74; placebo n = 37)

AnalysesHR (95% CI)P*
Treatment only1.012 (0.651-1.572)0.958
Prerandomization stratification factors (4)0.937 (0.596-1.472)0.776
Factors imbalanced between erlotinib and placebo (6)1.033 (0.652-1.636)0.890
  • Abbreviations: CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.

  • * P value not adjusted for multiplicity.

  • Prior response (CR/PR versus SD/PD).

  • Factors imbalanced between erlotinib and placebo: baseline ECOG performance status (0-1 versus 2-3), response to prior therapy (CR/PR versus SD/PD), number of prior therapies (1 versus 2), smoking history (yes versus no), sex, and histology (adenocarcinoma versus others).